2019
Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts
Laird J, Lok B, Carney B, Kossatz S, de Stanchina E, Reiner T, Poirier J, Rudin C. Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts. Journal Of Thoracic Oncology 2019, 14: 1743-1752. PMID: 31195178, PMCID: PMC6764879, DOI: 10.1016/j.jtho.2019.05.032.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCell ProliferationFemaleFluorine RadioisotopesHumansLung NeoplasmsMiceMice, Inbred NODMice, SCIDPhthalazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPositron-Emission TomographyRadiopharmaceuticalsSmall Cell Lung CarcinomaTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsPatient-derived xenograftsPositron emission tomographicPARP inhibitorsTherapeutic efficacyTarget engagementPositron emission tomographic imagingDifferential therapeutic efficacyTumor radiotracer uptakeTumor growth inhibitionEnzyme-linked immunosorbentDose-dependent mannerFluorine-18Oral talazoparibMultiple dosesSingle dosesTotal tumorsPolymerase-1 (PARP-1) inhibitorsPET uptakeRadiotracer uptakeInhibitor of polyIndividual tumorsPET/Drug efficacyTalazoparib treatmentPromising therapeutics
2018
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
Laird J, Lok B, Ma J, Bell A, de Stanchina E, Poirier J, Rudin C. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clinical Cancer Research 2018, 24: 5143-5152. PMID: 29945991, PMCID: PMC6742772, DOI: 10.1158/1078-0432.ccr-18-0401.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalDisease Models, AnimalDNA Breaks, Double-StrandedDose-Response Relationship, DrugHumansPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsRadiation ToleranceRadiation, IonizingRadiation-Sensitizing AgentsSmall Cell Lung CarcinomaXenograft Model Antitumor AssaysConceptsSmall cell lung cancerSCLC cell linesClonogenic survival assaysCell linesPatient-derived xenograft modelsPARP inhibitionShort-term viability assaysDoses of veliparibCell lung cancerClin Cancer ResEfficacy of radiotherapyTumor growth inhibitionViability assaysAggressive malignancyLung cancerPDX modelsNovel therapiesSCLC cellsXenograft modelSingle agentPARP inhibitorsCancer ResTalazoparibSurvival assaysContribution of PARP
2017
Unravelling the biology of SCLC: implications for therapy
Sabari J, Lok B, Laird J, Poirier J, Rudin C. Unravelling the biology of SCLC: implications for therapy. Nature Reviews Clinical Oncology 2017, 14: 549-561. PMID: 28534531, PMCID: PMC5843484, DOI: 10.1038/nrclinonc.2017.71.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsGenomeHumansImmunotherapyLung NeoplasmsMolecular Targeted TherapyMutationProteomicsSmall Cell Lung CarcinomaConceptsBiology of SCLCHigh-grade neuroendocrine tumorsPARP inhibitor veliparibImmune checkpoint blockadeEncouraging clinical activityPoor overall survivalHigh mutational burdenImmune checkpoint proteinsZeste homologue 2Antibody-drug conjugatesOverall survivalRovalpituzumab tesirineLung cancerNeuroendocrine tumorsClinical trialsClinical activityMutational burdenNew therapiesTherapeutic targetingProtein 3SCLCHomologue 2PatientsPromising activityTherapy